Nexalin Technology, Inc. has received a Notice of Allowance from the USPTO for its patent application on a non-invasive, drug-free solution for substance use disorders. The Deep Intracranial Frequency Stimulation (DIFS) technology aims to assist individuals struggling with opioid use disorder, alcohol use disorder, and stimulant addiction. CEO Mark White sees this patent as a key step in providing innovative healthcare solutions for urgent challenges like substance use disorders. The DIFS technology offers a drug-free, non-invasive alternative that may help ease withdrawal symptoms and support long-term recovery without the risks associated with traditional treatments. CMO David Owens emphasizes the importance of addressing the pressing public health crisis of substance use disorders and highlights Nexalin’s commitment to advancing new solutions through their proprietary technology. Nexalin’s expanding intellectual property portfolio includes cutting-edge advancements in non-invasive brain stimulation for mental health, addiction, and neurological disorders. As Nexalin continues to develop next-generation solutions, the focus remains on breakthrough technologies that improve patient outcomes in mental health and addiction treatment. For more information about Nexalin Technology and its innovative medical technology solutions, visit www.nexalin-usa.com.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
